American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited
- PMID: 22123290
- DOI: 10.1097/MOU.0b013e32834d8e87
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited
Abstract
Purpose of review: The purpose of this review is to provide a complete revision of two of the most widely used clinical guidelines in the management of lower urinary tract symptoms induced by benign prostatic hyperplasia and their importance and compliance among urologists.
Recent findings: Updates of the American Association of Urology and European Association of Urology clinical practice guidelines (CPGs) were reviewed and analyzed. Literature concerning compliance and application of these two CPGs in the different working scenarios of practicing has been evaluated.
Summary: Urology has moved to an era in which costs and quality of care are being scrutinized, and compliance to CPGs will be assessed. Practicing urologists do not have the time to keep up to date with the continuous incoming literature and CPGs are a great tool to give the highest quality of care to our patients.
Similar articles
-
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.J Urol. 2011 Sep;186(3):971-6. doi: 10.1016/j.juro.2011.04.081. Epub 2011 Jul 24. J Urol. 2011. PMID: 21791352
-
Diagnosis and medical treatment of lower urinary tract symptoms in adult men: applying specialist guidelines in clinical practice.BJU Int. 2012 Sep;110(5):710-8. doi: 10.1111/j.1464-410X.2011.10808.x. Epub 2011 Dec 7. BJU Int. 2012. PMID: 22145967
-
The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion.Can J Urol. 2004 Apr;11(2):2186-93. Can J Urol. 2004. PMID: 15182407
-
Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care.Curr Opin Urol. 2018 May;28(3):262-266. doi: 10.1097/MOU.0000000000000504. Curr Opin Urol. 2018. PMID: 29601306 Review.
-
Translation of benign prostatic hyperplasia guidelines into clinical practice.Curr Opin Urol. 2008 Jan;18(1):56-60. doi: 10.1097/MOU.0b013e3282f13bbf. Curr Opin Urol. 2008. PMID: 18090491 Review.
Cited by
-
Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.World J Urol. 2021 Jul;39(7):2635-2643. doi: 10.1007/s00345-020-03517-0. Epub 2020 Dec 18. World J Urol. 2021. PMID: 33337513 Free PMC article.
-
Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.Front Pharmacol. 2020 May 8;11:658. doi: 10.3389/fphar.2020.00658. eCollection 2020. Front Pharmacol. 2020. PMID: 32457631 Free PMC article. Review.
-
Comprehensive urinary metabolomic characterization of a genetically induced mouse model of prostatic inflammation.Int J Mass Spectrom. 2018 Nov;434:185-192. doi: 10.1016/j.ijms.2018.09.017. Epub 2018 Sep 22. Int J Mass Spectrom. 2018. PMID: 30872949 Free PMC article.
-
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012615. doi: 10.1002/14651858.CD012615.pub2. Cochrane Database Syst Rev. 2017. PMID: 29161773 Free PMC article. Review.
-
In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.Sci Rep. 2016 Aug 9;6:30869. doi: 10.1038/srep30869. Sci Rep. 2016. PMID: 27502322 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
